Literature DB >> 10406360

Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study.

M A Nobbenhuis1, J M Walboomers, T J Helmerhorst, L Rozendaal, A J Remmink, E K Risse, H C van der Linden, F J Voorhorst, P Kenemans, C J Meijer.   

Abstract

BACKGROUND: A relation has been established between infection with high-risk types of human papillomavirus and development of cervical cancer. We investigated a role for testing for human papillomavirus as part of cervical-cancer screening.
METHODS: We monitored by cytology, colposcopy, and testing for high-risk human papillomavirus 353 women referred to gynaecologists with mild to moderate and severe dyskaryosis. The median follow-up time was 33 months. At the last visit we took biopsy samples. Our primary endpoint was clinical progression, defined as cervical intraepithelial neoplasia (CIN) 3, covering three or more cervical quadrants on colposcopy, or a cervical-smear result of suspected cervical cancer.
FINDINGS: 33 women reached clinical progression. All had persistent infection with high-risk human papillomavirus. The cumulative 6-year incidence of clinical progression among these women was 40% (95% CI 21-59). In women with end histology CIN 3, 98 (95%) of 103 had persistent infection with high-risk human papillomavirus from baseline. Among women with mild to moderate dyskaryosis at baseline, a second test for human papillomavirus at 6 months predicted end histology CIN 3 better than a second cervical smear.
INTERPRETATION: Persistent infection with high-risk human papillomavirus is necessary for development and maintenance of CIN 3. All women with severe dyskaryosis should be referred to gynaecologists, whereas women with mild to moderate dyskaryosis should be referred only after a second positive test for high-risk human papillomavirus at 6 months.

Entities:  

Mesh:

Year:  1999        PMID: 10406360     DOI: 10.1016/S0140-6736(98)12490-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  110 in total

Review 1.  Cervical cytology after 2000: where to go?

Authors:  C J Meijer; J M Walboomers
Journal:  J Clin Pathol       Date:  2000-01       Impact factor: 3.411

2.  Improved amplification of genital human papillomaviruses.

Authors:  P E Gravitt; C L Peyton; T Q Alessi; C M Wheeler; F Coutlée; A Hildesheim; M H Schiffman; D R Scott; R J Apple
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

3.  A novel strategy for human papillomavirus detection and genotyping with SybrGreen and molecular beacon polymerase chain reaction.

Authors:  K Szuhai; E Sandhaus; S M Kolkman-Uljee; M Lemaître; J C Truffert; R W Dirks; H J Tanke; G J Fleuren; E Schuuring; A K Raap
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

4.  Screening for cervical cancer: should we test for infection with high-risk HPV?

Authors:  C J Meijer; P J Snijders; A J van den Brule
Journal:  CMAJ       Date:  2000-09-05       Impact factor: 8.262

5.  Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.

Authors:  N R Chu; H B Wu; T Wu; L J Boux; M I Siegel; L A Mizzen
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

6.  Persistence of newly detected human papillomavirus type 31 infection, stratified by variant lineage.

Authors:  Long Fu Xi; Mark Schiffman; Laura A Koutsky; Zhonghu He; Rachel L Winer; Ayaka Hulbert; Shu-Kuang Lee; Yang Ke; Nancy B Kiviat
Journal:  Int J Cancer       Date:  2012-07-11       Impact factor: 7.396

7.  Type-specific multiple sequencing primers: a novel strategy for reliable and rapid genotyping of human papillomaviruses by pyrosequencing technology.

Authors:  Baback Gharizadeh; Maria Oggionni; Biying Zheng; Edit Akom; Nader Pourmand; Afshin Ahmadian; Keng-Ling Wallin; Pål Nyrén
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

8.  Comparison of non-invasive sampling methods for detection of HPV in rural African women.

Authors:  N Lack; B West; D Jeffries; G Ekpo; L Morison; W P Soutter; G Walraven; L Boryseiwicz
Journal:  Sex Transm Infect       Date:  2005-06       Impact factor: 3.519

9.  Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults.

Authors:  Daniel C Beachler; Elizabeth A Sugar; Joseph B Margolick; Kathleen M Weber; Howard D Strickler; Dorothy J Wiley; Ross D Cranston; Robert D Burk; Howard Minkoff; Susheel Reddy; Weihong Xiao; Yingshi Guo; Maura L Gillison; Gypsyamber D'Souza
Journal:  Am J Epidemiol       Date:  2014-12-04       Impact factor: 4.897

10.  High prevalence of human papillomavirus (HPV) infections and high frequency of multiple HPV genotypes in human immunodeficiency virus-infected women in Brazil.

Authors:  José E Levi; Bernhard Kleter; Wim G V Quint; Maria C S Fink; Cynthia L M Canto; Regina Matsubara; Iara Linhares; Aluísio Segurado; Bart Vanderborght; José Eluf Neto; Leen-Jan Van Doorn
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.